Management of Moderate Hypertriglyceridemia (200 – 499 mg/dL)

Initial Assessment & Lipid Profiling

• Obtain a complete fasting lipid panel—including LDL‑C, HDL‑C, and non‑HDL‑C—to guide comprehensive lipid management, as recommended by the ACC/AHA guidelines. 1, 2

Therapeutic Lifestyle Changes (First‑Line for All Patients)

Dietary Modifications

• Reduce saturated fat intake to < 7 % of total calories, dietary cholesterol to < 200 mg/day, and trans fat to < 1 % of energy to lower triglycerides. (ACC/AHA) 1, 2

Omega‑3 Intake

• Increase omega‑3 fatty acids through fish consumption; supplementation with 2–4 g/day of EPA/DHA is reasonable for triglyceride reduction. (ACC/AHA) 1, 2

Physical Activity & Weight Management

• Perform 30–60 minutes of moderate‑intensity aerobic activity on most days. (ACC/AHA) 3, 4
• Aim for a body‑mass index of 18.5–24.9 kg/m² in overweight or obese individuals. (ACC/AHA) 3, 4

Alcohol & Other Lifestyle Factors

• Minimize or eliminate alcohol consumption in patients with elevated triglycerides. (ACC/AHA) 1, 2

Pharmacologic Treatment Algorithm

Statin Therapy – Primary Pharmacologic Intervention

• Initiate statin therapy as first‑line medication for patients with triglycerides 200–499 mg/dL because statins lower LDL‑C, modestly reduce triglycerides, and provide proven cardiovascular benefit. (ACC/AHA) 1, 2
• Target non‑HDL‑C < 130 mg/dL in this triglyceride range; further reduction to < 100 mg/dL is reasonable for additional risk reduction. (ACC/AHA) 1, 3, 2, 4
• High‑dose statins achieve moderate triglyceride lowering and may lessen the need for combination therapy. (ACC/AHA) 5, 6

Adding Fibrate or Niacin After LDL‑C Lowering

• If triglycerides remain 200–499 mg/dL despite statin therapy, consider adding a fibrate (fenofibrate or gemfibrozil) to further lower triglycerides and non‑HDL‑C. (ACC/AHA) 1, 2, 7
• Niacin can be added after LDL‑C lowering, but evidence shows only trivial cardiovascular benefit and a higher incidence of adverse effects. (ACC/AHA) 1, 2, 7, 8
• Combination of high‑dose statin with a fibrate increases the risk of severe myopathy; when this combination is used, keep the statin dose relatively low. (ACC/AHA) 2, 7
• Gemfibrozil carries a higher myopathy risk when combined with statins compared with fenofibrate; fenofibrate is preferred. (ACC/AHA) 5, 6

Safety Considerations & Contraindicated Agents

• Bile‑acid sequestrants are relatively contraindicated when triglycerides exceed 200 mg/dL. (ACC/AHA) 1, 2
• Over‑the‑counter niacin supplements should not replace prescription niacin for triglyceride management. (ACC/AHA) 2, 7
• Do not combine gemfibrozil with statins; fenofibrate has a lower myopathy risk. (ACC/AHA) 5, 6
• Omega‑3 dietary supplements containing combined EPA/DHA lack proven ASCVD risk‑reduction benefit and should not be relied upon for cardiovascular protection. (ACC/AHA) 9

Risk Thresholds & Pancreatitis Prevention

• Triglyceride levels ≥ 500 mg/dL are associated with an increased risk of acute pancreatitis; levels < 500 mg/dL (e.g., 350 mg/dL) are not considered an immediate pancreatitis risk. (ACC/AHA) 1, 2, 9
• When triglycerides are ≥ 500 mg/dL, initiate fibrate or niacin before LDL‑C‑lowering therapy to mitigate pancreatitis risk. (ACC/AHA) 1, 2, 7
• For triglycerides ≥ 1,000 mg/dL, implement extreme dietary fat restriction (< 5 % of calories) and aggressive pharmacotherapy. (ACC/AHA) 9

Monitoring & Follow‑Up

• Reassess the fasting lipid panel 4–12 weeks after initiating lifestyle changes or pharmacologic therapy to evaluate response. (ACC/AHA) 1, 2
• Optimize glycemic control in patients with diabetes, as improved glucose management markedly lowers triglycerides. (ACC/AHA) 5, 6, 9
• Adjust therapy based on achievement of non‑HDL‑C targets and the overall cardiovascular risk profile. (ACC/AHA) 1, 2
• Monitor for signs of myopathy when statins are combined with fibrates or niacin, especially in individuals with renal impairment. (ACC/AHA) 5, 6